Repligen Co. (NASDAQ:RGEN) Holdings Decreased by Federated Hermes Inc.

Federated Hermes Inc. reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 321,402 shares of the biotechnology company’s stock after selling 183 shares during the quarter. Federated Hermes Inc.’s holdings in Repligen were worth $40,516,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Evoke Wealth LLC purchased a new position in Repligen in the 4th quarter worth about $1,955,000. Norden Group LLC increased its stake in Repligen by 1,711.6% in the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after purchasing an additional 36,663 shares in the last quarter. Artemis Investment Management LLP increased its stake in Repligen by 33.8% in the 1st quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after purchasing an additional 42,380 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Repligen by 30.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after purchasing an additional 6,705 shares in the last quarter. Finally, Congress Asset Management Co. MA increased its stake in Repligen by 14.6% in the 1st quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after purchasing an additional 11,213 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Down 1.4 %

RGEN opened at $139.99 on Friday. The business has a 50 day moving average price of $145.43 and a 200 day moving average price of $157.11. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The firm has a market cap of $7.84 billion, a P/E ratio of 559.98, a price-to-earnings-growth ratio of 4.24 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same period in the previous year, the company earned $0.53 EPS. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Research analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on RGEN shares. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. UBS Group lowered their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $190.00 target price on shares of Repligen in a research note on Wednesday, July 31st. Finally, Guggenheim began coverage on Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $188.38.

Insider Transactions at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.